5月26日，泰山石油今日收盘6.27元，上涨1.13%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到22.54倍，总市值30.15亿元。 从行业市盈率排名来看，公司所处的石油行业行业市盈率平均12.63倍，行业中值25.57倍，泰山石油排 名第14位。 股东方面，截至2025年5月20日，泰山石油股东户数34768户，较上次减少416户，户均持股市值35.28万 元，户均持股数量2.76万股。 最新一期业绩显示，2025年一季报，公司实现营业收入8.02亿元，同比-4.76%；净利润5296.57万元，同 比185.74%，销售毛利率17.68%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)14泰山石油22.5430.352.7630.15亿行业平均 12.6311.321.171698.99亿行业中值25.5729.381.5653.24亿1茂化实华-26.67-23.823.2419.86亿2沈阳化 工-25.70-18.142.1630.49亿3中晟高科-20.05-13.477.4922.93亿4博汇股份-9.52-7.917.2124.28亿5国际实 业-5.92-5.9 ...

Group 1 - The core viewpoint of the articles highlights that Mindray Medical's stock closed at 231.9 yuan, with a 2.79% increase, and a rolling PE ratio of 25.25 times, while the total market capitalization reached 281.165 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 48.79 times and a median of 35.20 times, Mindray Medical ranks 57th in terms of PE ratio [1][2] - The latest financial performance indicates that for Q1 2025, the company reported a revenue of 8.237 billion yuan, a year-on-year decrease of 12.12%, and a net profit of 2.629 billion yuan, down 16.81%, with a gross profit margin of 62.53% [1] Group 2 - The main business of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. includes the research, manufacturing, marketing, and service of medical devices, with key products in life information and support, in vitro diagnostics, medical imaging, electrophysiology, and vascular intervention [1] - On May 23, the net outflow of main funds for Mindray Medical was 141.775 million yuan, indicating a trend of outflow over the past five days, totaling 4.0746 million yuan [1]

Group 1 - The core viewpoint of the news is that Shennong Group's stock has declined significantly, with a closing price of 27.06 yuan and a rolling PE ratio of 15.45 times, which is considerably lower than the industry average of 42.62 times [1] - As of the first quarter of 2025, Shennong Group has 12 institutional investors holding a total of 59.48 million shares, with a market value of 1.689 billion yuan [1] - The company's main business includes feed processing and sales, pig farming and sales, pig slaughtering, and fresh pork food sales, with key products being feed, commodity pigs, piglets, and various pork products [1] Group 2 - In the latest financial report for the first quarter of 2025, Shennong Group achieved an operating income of 1.472 billion yuan, representing a year-on-year increase of 35.97%, and a net profit of 229 million yuan, showing a remarkable year-on-year growth of 6510.85% [1] - The sales gross margin for the company stands at 22.90% [1] - In terms of market capitalization, Shennong Group is valued at 14.202 billion yuan [2]

Core Insights - The stock price of Huamao Logistics closed at 6.43 yuan, down 2.28%, with a rolling PE ratio of 17.18 times and a total market capitalization of 8.417 billion yuan [1] - The average PE ratio for the logistics industry is 24.60 times, with a median of 23.53 times, placing Huamao Logistics at the 27th position in the industry ranking [1] - As of the first quarter of 2025, seven institutions held shares in Huamao Logistics, with a total holding of 658.1514 million shares valued at 3.745 billion yuan [1] Company Overview - Huamao International Logistics Co., Ltd. specializes in third-party international comprehensive logistics and international logistics solutions [1] - The main products offered by the company include comprehensive logistics services, international air and sea freight, cross-border e-commerce logistics, special logistics, third-party warehousing logistics, international engineering logistics, and railway freight forwarding [1] - According to the latest rankings by the authoritative global logistics magazine "Transport Topics," Huamao Logistics ranks 16th among the top 50 global sea and air freight forwarders, indicating its competitive position in the international logistics market [1] Financial Performance - In the first quarter of 2025, Huamao Logistics reported an operating revenue of 3.992 billion yuan, a year-on-year increase of 2.82%, while net profit was 118 million yuan, reflecting a year-on-year decrease of 29.42% [1] - The sales gross margin for the company stood at 11.39% [1]

Group 1 - The core viewpoint of the articles highlights Huaneng International's current stock performance, with a closing price of 7.4 yuan and a rolling PE ratio of 11.05 times, significantly lower than the industry average of 23.46 times [1][2] - Huaneng International's total market capitalization is reported at 116.166 billion yuan, ranking 14th in the electricity sector based on PE ratio [1][2] - The company has a total of 106,310 shareholders as of March 31, 2016, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Huaneng International's main business involves power generation and sales, with additional services in port and transportation [1] - The latest quarterly report for Q1 2025 shows a revenue of 60.335 billion yuan, a year-on-year decrease of 7.70%, while net profit increased by 8.19% to 4.973 billion yuan, with a gross margin of 19.05% [1] - The company holds a total of 2,021 patents, including 1,021 invention patents, 746 utility model patents, and 316 international patents [1]

Group 1 - The core viewpoint of the news is that Aide Biological's stock is underperforming compared to its industry peers, with a current PE ratio of 28.21, significantly lower than the industry average of 48.71 [1][2] - Aide Biological's market capitalization is reported at 7.932 billion yuan, ranking 65th in the medical device industry based on PE ratio [1][2] - The company experienced a net outflow of 9.8921 million yuan in principal funds on May 22, with a total outflow of 8.7322 million yuan over the past five days [1] Group 2 - Aide Biological specializes in tumor gene testing reagents, software, and supporting instruments, as well as providing testing services and drug clinical research services [1] - For the first quarter of 2025, Aide Biological reported revenue of 272 million yuan, a year-on-year increase of 16.63%, and a net profit of 90.4718 million yuan, reflecting a year-on-year growth of 40.92% [1] - The company's gross profit margin stands at 83.48% [1]

Group 1 - The core viewpoint of the articles indicates that Mingde Biological's stock is currently underperforming with a closing price of 19.0 yuan, down 1.91%, and a rolling PE ratio of 113.85 times, significantly higher than the industry average [1][2] - The total market capitalization of Mingde Biological is reported at 4.418 billion yuan, ranking 108th in the medical device industry based on PE ratio [1][2] - The company experienced a net outflow of 4.511 million yuan in major funds on May 22, with a total outflow of 11.4719 million yuan over the past five days, indicating a negative trend in investor sentiment [1] Group 2 - Mingde Biological specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as providing information solutions for critical care and third-party medical testing services [1] - The latest financial report for Q1 2025 shows that the company achieved operating revenue of 69.9603 million yuan, a year-on-year increase of 14.76%, but reported a net loss of approximately 3.662988 million yuan, a year-on-year decline of 111.43%, with a gross profit margin of 16.37% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Lingdian Electric Control, indicating a significant drop in stock price and a high PE ratio compared to industry averages [1][2] - As of May 21, Lingdian Electric Control's stock closed at 55.58 yuan, down 3.02%, with a rolling PE ratio of 87.15 times and a total market capitalization of 2.88 billion yuan [1] - The average PE ratio for the automotive parts industry is 43.40 times, with a median of 36.59 times, placing Lingdian Electric Control at the 193rd position in the industry ranking [1][2] Group 2 - As of the first quarter of 2025, four institutions held shares in Lingdian Electric Control, with a total holding of 4.71 million shares valued at 228 million yuan [1] - The company's main business includes engine management systems, electric vehicle power electronic control systems, hybrid vehicle power electronic control systems, and related technology development and calibration services [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 312 million yuan, a year-on-year increase of 21.55%, and a net profit of 17.476 million yuan, a year-on-year increase of 4521.16%, with a gross profit margin of 18.59% [1]

Group 1 - The core viewpoint of the article highlights the performance and valuation of Aidi Te (爱迪特), indicating a recent stock price increase and a low rolling PE ratio compared to the industry average [1] - As of May 20, Aidi Te's closing price was 56.11 yuan, with a rolling PE ratio of 26.95, marking a new low in 31 days, and a total market capitalization of 4.271 billion yuan [1] - The company ranks 59th in the medical device industry, which has an average PE ratio of 49.51 and a median of 36.17 [2] Group 2 - Aidi Te experienced a net outflow of 351,100 yuan in principal funds on May 20, with a total outflow of 1.749 million yuan over the past five days [1] - The company's main business includes the research, production, and sales of dental restoration materials and the design and sales of dental digital equipment [1] - In the latest quarterly report for Q1 2025, Aidi Te achieved an operating income of 205 million yuan, a year-on-year increase of 18.07%, and a net profit of 31.271 million yuan, reflecting a year-on-year growth of 34.21% with a gross profit margin of 51.00% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhenghai Biological, which closed at 20.38 yuan, with a PE ratio of 30.35, marking a new low in 23 days, and a total market capitalization of 3.668 billion yuan [1] - Zhenghai Biological ranks 67th in the medical device industry, which has an average PE ratio of 49.51 and a median of 36.17 [1] - As of March 31, 2025, Zhenghai Biological had 16,966 shareholders, a decrease of 193 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - The main business of Zhenghai Biological involves the research, production, and sales of bio-regenerative materials, including oral repair membranes, absorbable dura mater patches, bone repair materials, and surgical sponges [1] - The company was recognized as one of the top 50 new material leading enterprises in Shandong Province for 2023, as announced by the Shandong Provincial Department of Industry and Information Technology [1] - In the latest quarterly report for Q1 2025, Zhenghai Biological reported revenue of 97.42 million yuan, a year-on-year increase of 8.68%, and a net profit of 26.63 million yuan, a year-on-year decrease of 34.06%, with a gross profit margin of 80.96% [1]